These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23133883)

  • 21. Descriptive Epidemiology of Generalized Anxiety Disorder in Canada.
    Watterson RA; Williams JV; Lavorato DH; Patten SB
    Can J Psychiatry; 2017 Jan; 62(1):24-29. PubMed ID: 27310239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generalized anxiety disorder: nature and course.
    Wittchen HU; Hoyer J
    J Clin Psychiatry; 2001; 62 Suppl 11():15-9; discussion 20-1. PubMed ID: 11414546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anxiety disorders in private practice psychiatric out-patients: prevalence, comorbidity and burden (DELTA study)].
    Pélissolo A; André C; Chignon JM; Dutoit D; Martin P; Richard-Berthe C; Tignol J
    Encephale; 2002; 28(6 Pt 1):510-9. PubMed ID: 12506263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The epidemiology of pure and comorbid generalized anxiety disorder: a review and evaluation of recent research.
    Kessler RC
    Acta Psychiatr Scand Suppl; 2000; (406):7-13. PubMed ID: 11131470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating generalized anxiety disorder with cognitive-behavioral therapy.
    Lang AJ
    J Clin Psychiatry; 2004; 65 Suppl 13():14-9. PubMed ID: 15384932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Goals and challenges of optimally treating depression in a managed care environment.
    Manag Care; 2002 Aug; 11(8 Suppl):3-6. PubMed ID: 12233201
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications.
    Casacalenda N; Boulenger JP
    Can J Psychiatry; 1998 Sep; 43(7):722-30. PubMed ID: 9773222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.
    Rovira J; Albarracin G; Salvador L; Rejas J; Sánchez-Iriso E; Cabasés JM
    Community Ment Health J; 2012 Jun; 48(3):372-83. PubMed ID: 22484993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary management of comorbid anxiety and depression in geriatric patients.
    Doraiswamy PM
    J Clin Psychiatry; 2001; 62 Suppl 12():30-5. PubMed ID: 11430616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescribing patterns for depression and anxiety worldwide.
    Lecrubier Y
    J Clin Psychiatry; 2001; 62 Suppl 13():31-6; discussion 37-8. PubMed ID: 11434416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dynamic view of comorbid depression and generalized anxiety disorder symptom change in chronic heart failure: the discrete effects of cognitive behavioral therapy, exercise, and psychotropic medication.
    Tully PJ; Selkow T; Bengel J; Rafanelli C
    Disabil Rehabil; 2015; 37(7):585-92. PubMed ID: 24981015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
    Bereza BG; Machado M; Einarson TR
    Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations between diabetes, major depressive disorder and generalized anxiety disorder comorbidity, and disability: findings from the 2012 Canadian Community Health Survey--Mental Health (CCHS-MH).
    Deschênes SS; Burns RJ; Schmitz N
    J Psychosom Res; 2015 Feb; 78(2):137-42. PubMed ID: 25510185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generalised anxiety disorder in elderly patients : epidemiology, diagnosis and treatment options.
    Flint AJ
    Drugs Aging; 2005; 22(2):101-14. PubMed ID: 15733018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study.
    Perlis RH; Mehta R; Edwards AM; Tiwari A; Imbens GW
    Depress Anxiety; 2018 Oct; 35(10):946-952. PubMed ID: 29734486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with the type of psychotropic medications purchased for common mental disorders in the largest managed care organization in Israel.
    Ayalon L; Gross R; Yari A; Feldhamer E; Balicer RD; Goldfracht M
    Int J Psychiatry Med; 2012; 44(1):91-102. PubMed ID: 23356096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Summary: defining remission in patients treated with antidepressants.
    Thase ME
    J Clin Psychiatry; 1999; 60 Suppl 22():35-6. PubMed ID: 10634354
    [No Abstract]   [Full Text] [Related]  

  • 39. Association between Physicians' Adherence to a Pharmacotherapy Guideline and Continuity of Care for Patients with Depression and/or Anxiety Disorder.
    Heidari E; Eslami S; Abolhassani F; Sharifi V; Taherzadeh Z; Daneshvar T
    Arch Iran Med; 2017 May; 20(5):308-313. PubMed ID: 28510467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety.
    Ballenger JC; Davidson JR; Lecrubier Y; Nutt DJ; Borkovec TD; Rickels K; Stein DJ; Wittchen HU
    J Clin Psychiatry; 2001; 62 Suppl 11():53-8. PubMed ID: 11414552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.